Protalix BioTherapeutics (PLX) Retained Earnings (2010 - 2025)
Protalix BioTherapeutics' quarterly Retained Earnings came in at -$385.0 million in Q4 2025, down 1.75% year-on-year from -$391.8 million in Q4 2024, and down 1.75% quarter-over-quarter from -$378.4 million in Q4 2024.
Protalix BioTherapeutics has reported Retained Earnings for 16 years, with the latest figure at -$385.0 million in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 1.75% year-over-year to -$385.0 million; the trailing twelve-month figure through Dec 2025 stood at -$385.0 million (down 1.75% YoY), and the FY2025 full-year result was -$385.0 million, down 1.75% from the prior year.
- Retained Earnings for Q4 2025 stood at -$385.0 million, down from -$378.4 million in the prior quarter.
- The five-year high for Retained Earnings was -$374.9 million in Q4 2021, with the low at -$389.9 million in Q4 2022.
- Average Retained Earnings over 5 years is -$381.9 million, with a median of -$381.5 million recorded in 2023.
- Year-over-year, Retained Earnings fell 7.94% in 2021 and gained 2.13% in 2023.
- Tracing PLX's Retained Earnings over 5 years: stood at -$374.9 million in 2021, then slipped by 3.98% to -$389.9 million in 2022, then climbed by 2.13% to -$381.5 million in 2023, then climbed by 0.83% to -$378.4 million in 2024, then dropped by 1.75% to -$385.0 million in 2025.
- The last three Retained Earnings figures came in at -$385.0 million (Q4 2025), -$378.4 million (Q4 2024), and -$381.5 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -385.00 Mn |
| Dec 31, 2024 | -378.39 Mn |
| Dec 31, 2023 | -381.55 Mn |
| Dec 31, 2022 | -389.86 Mn |
| Dec 31, 2021 | -374.93 Mn |
| Dec 31, 2020 | -347.35 Mn |
| Dec 31, 2019 | -340.83 Mn |
| Dec 31, 2018 | -322.55 Mn |
| Dec 31, 2017 | -296.10 Mn |
| Dec 31, 2016 | -212.66 Mn |
| Dec 31, 2015 | -183.29 Mn |
| Dec 31, 2014 | -241.33 Mn |
| Dec 31, 2013 | -211.39 Mn |
| Dec 31, 2012 | -183.60 Mn |
| Dec 31, 2011 | -171.98 Mn |
| Dec 31, 2010 | -135.45 Mn |